In preclinical models of Wistar scientists from the Institute have developed a new synthetic broad-spectrum protection against viruses strategy based on DNA. The study is published in Vaccines.
Strains of flu change every year. Seasonal influenza vaccine effective against strains. Following the development of new drugs are launched into production for use in an influenza season.
"A related process is not perfect, so some of the seasonal flu vaccine is available in the autumn, is not suitable for the circulating virus strains and less effective, - says senior author David Weiner -. Sometimes flu strains can drastically change, leading to a pandemic strain, which requires a new strategy for the development of drugs, which comes as a result of the risk of serious health effects. In addition, some vulnerable groups may not respond to the new vaccine. "
Flu vaccines work by inducing the immune system to produce soluble proteins, called antibodies, which target the exact types of influenza virus included in the preparation of medicines. These antibodies protect against certain strains of influenza virus in the vaccine, but do not provide complete protection against other influenza strains.
"We have developed another method of vaccination strategies, and instead rely on the immune system to respond to the drug, a new strategy of working with DNA that encodes a directly protective antibodies - said study author Sarah Tar Elliott, Ph.D., doctoral weiner laboratory -. New synthetic DNA strategy, called DMAB, provides monoclonal antibodies that provide protection against influenza strains highly ".
Scientists have studied the DNA sequences of two human antibodies that can target the influenza A viruses, so they can hit the influenza virus B. Scientists have focused on these antibodies targeting two types of influenza viruses that contain all the strains that cause disease in humans.
If after studying mouse models for further experimentation on humans are successful, this research will help in the prevention of influenza and other infectious diseases.
"Despite the fact that this pre-clinical work, the strategy requires further study because it is a simple and economical way to overcome the limitations of current strategies against influenza vaccine will provide protection against seasonal and pandemic influenza," - the researchers added.